Phase I

Trial

Single center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study of EHP-101

Objective

Evaluate the Safety and Tolerability, Pharmacokinetics, Food-effect and Pharmacodynamics of EHP-101 in Healthy Volunteers

Status

Completed | LEARN MORE

ClinicalTrials.gov Identifier: NCT03745001

Phase IIa

Trial

Double-Blind, Randomized, Intracohort Placebo-Controlled, Multicenter Study of EHP-101

Objective

Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 in Patients With Diffuse Cutaneous Systemic Sclerosis

Status

Initiating enrollment in the United States, Australia, and New Zealand. We plan to enroll approximately 36 patients in a total of an estimated 30 centers and anticipate starting to get preliminary results around the end of 2020 and the beginning of 2021, with final data in the second half of 2021

ClinicalTrials.gov Identifier: NCT04166552